Commentary: "Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease" by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519

Harma Alma*, Corina de Jong, Janwillem Kocks, Thys van der Molen

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

59 Downloads (Pure)

Cite this